Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E.
Target Price
The average target price of ARQT is 33 and suggests 45% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell